Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001193125-25-277861·Lyell Immunopharma, Inc.
Schedule 13G ownership disclosure
Lyell Immunopharma Inc
Common Stock, $0.0001 par value per share · CUSIP: 55083R203
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Newton (PTC) Limited
Shares: 754,698 · Class: 3.93%
- Orland Properties Limited
Shares: 754,698 · Class: 3.93%
- Gemini GP Limited
Shares: 754,698 · Class: 3.93%
- Gemini Investments, L.P.
Shares: 754,698 · Class: 3.93%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-277861
- Form type
- SCHEDULE 13G/A
- Filer
- Lyell Immunopharma, Inc.
- CIK
- CIK 1806952
- Filed
- Nov 12, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership